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 Abstract  
Background: Parkinson’s disease (PD) management comprises of drug treatments, surgery 
and physical activity/occupational therapies to relieve PD’s symptoms. The aim of this study 
is twofold; firstly, to appraise recent economic evaluation studies on PD management in order 
to update the existing knowledge and, secondly, to facilitate decision making on PD 
management by assessing the cost-effectiveness of all types of PD interventions.  
Methods: A systematic search for studies published between 2010 and 2018 was conducted. 
The inclusion and exclusion of the articles were based on criteria relevant to Population, 
Intervention, Comparison, Outcomes and Study design (PICO). The reporting quality of the 
articles was assessed according to Consolidated Health Economic Evaluation Reporting 
Standards.  
Results: Twenty eight articles were included, 10 of which were evaluations of drug 
treatments, 10 deep brain stimulation (DBS) and 8 physical/occupational therapies. Among 
early-stage treatments, Ti Ji dominated all physical activity interventions, however, its cost-
effectiveness should be further explored in relation to its duration, intensity, and frequency. 
Multidisciplinary interventions of joint medical and non-medical therapies provided slightly 
better health outcomes for the same costs. In advanced PD patients, adjunct drug treatments 
could become more cost-effective if introduced during early PD and, although DBS was more 
cost-effective than adjunct drug therapies, the results were time-bound.   
Conclusion: Conditionally, certain PD interventions are cost-effective. However, PD 
progression differs in each patient, thus the cost-effectiveness of individually-tailored 
combinations of interventions, which could provide more time in less severe disease states 
and improve patients’ and caregivers’ quality of life, should be further explored. 
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 Background  
Parkinson’s disease (PD) is the second most common neurodegenerative disease, after 
Alzheimer's, which causes severe morbidity and mortality globally 1 and leads to motor 
fluctuations, psychological and behavioral disorders. PD prevalence is estimated to affect 
nearly 1-2 per 1,000 people and is expected to double in the following 20-year timespan due 
to the intense demographic transition towards aging societies and extended life expectancy 2. 
The number of people with PD in Europe will increase by 33% by 2030 and will reach 1.2 
million people approximately in the USA by 20403. 
PD has major economic impacts on the patients, their families, and societies. Direct (medical, 
non-medical) and indirect (loss of productivity) PD costs in Europe reached € 7.7 billion in 
2010 4. In the USA, each PD patient bears $12,800 more medical expenses, expressed as 
healthcare visits and hospital inpatient days, and $10,000 more non-medical costs including 
absenteeism/ presenteeism of patients and informal caregivers, than those with the same 
characteristics but without PD 3. The costs of informal caregivers comprise an important 
subgroup of the total costs and are often greater than direct costs 5, 6. Furthermore, since the 
vast majority of PD patients are in need of informal care, these costs pose a significant 
burden 7. 
The causes of PD remain unknown; however, a combination of genetic and environmental 
factors possibly plays an important role in its genesis and progress 8. There is no cure for PD 
and existing treatments mainly relieve symptoms. Also, there is no early diagnostic test for 
PD so its diagnosis often occurs at a later stage after the symptoms have appeared 9. The most 
common and effective medication for PD symptomatology is levodopa 10. In its simplest 
form, oral levodopa has prolonged effect on increasing dopamine levels in the brain and 
restores movement functions 10. Apart from levodopa, Dopamine Agonists (DA) or MAO-B 
inhibitors (rasagiline and selegiline) can be used during the initial stages of PD11.  
Although oral levodopa conduces to long-lasting, adverse motor and psychological 
consequences, it could have short-term efficacy depending on its gastric absorption 12. Thus, 
oral levodopa can be either replaced by continuous infusion therapies like subcutaneous 
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 apomorphine and intraduodenal levodopa/carbidopa (Duodopa) or combined with MAO-B 
inhibitors and entacapone that can prolong levodopa’s short half-life and boost its 
effectiveness 10, 12-14. DA appear similar negative side effects only when they are used as an 
adjunct to levodopa 15, 16. 
As alternatives to drug therapies, surgical procedures, i.e. deep brain stimulation (DBS), 
stimulate the brain to decrease motor fluctuations in advanced PD patients 17 . DBS is based 
on the implantation of a medical device that induces electrical pulses to brain sites: the 
subthalamic nucleus (STN) or the globus pallidus internus (GPi). The pulses restore activity 
in neurons and improve patients’ mobility and functionality while reducing medication use 17, 
18. Besides the aforementioned interventions, there is also a positive effect of physical 
activity, occupational therapy and physiotherapy, complementary to drug treatment, on 
improving the motor and cognitive functions of PD patients in early stages 12, 19-22 . 
Researchers are interested in interventions that can offer relief of the symptoms and can lead 
to sustainable and long lasting health outcomes 2. 
Every intervention requires the utilization of scarce resources, thus economic evaluation is an 
expedient tool which facilitates decision making in regards to efficient use of resources 23. 
The bulk of economic evaluation studies in healthcare evaluate ways of allocating available 
resources in order to maximize population health 23. There are four main categories of 
economic evaluations; cost-effectiveness analysis (CEA), which measures outcomes in 
naturals units and compares the efficiency of alternative interventions targeting the same 
objective. Cost-utility analysis (CUA) measures outcomes in utility units (QALYs or 
DALYs) and, since it compares the intervention to other interventions, it can be used for 
optimal spending decisions. Cost-benefit analysis (CBA) presents both outcomes and costs in 
monetary units and informs about the amount of societal resources needed to achieve a goal, 
and lastly cost-minimization analysis (CMA), which assumes equal outcomes and compares 
only the costs 23.  
Current needs to ascertain PD interventions that provide the most efficient resource 
utilization (i.e. best outcomes for the occurring costs) imply constant reviews of the relevant 
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 economic evaluation studies. The systematic literature review is an effective method to 
identify the commonalities among the existing studies, highlight the knowledge gaps and 
provide recommendations for future research. There are several literature reviews of 
economic evaluations on PD 10, 24-28 which do not include studies after 2010. The exception is 
the study by Becerra et al., which, however, does not include all types of interventions 
simultaneously28. Thus, this paper has a twofold aim; to update the existing knowledge by 
appraising economic evaluations of PD interventions, and also to promote decision making 
on PD management by assessing the cost-effectiveness of all types of PD interventions.  
Methodology 
A systematic literature review was conducted for answering the research question in 
accordance with the PRISMA guidelines 29. Moreover, the Campbell and Cochrane 
Economics Methods Group guidelines 30 were followed for incorporating economic evidence 
including search criteria, data extraction, synthesis, and critical analysis. 
Search strategy 
A systematic search was performed to identify relevant articles published in both health 
economics and biomedical databases from 01.01.2010 till 31.12.2018. The databases 
searched were Medline (Pubmed), Embase and ECONbase, EconLit and Cumulative Index to 
Nursing and Allied Health (CINAHL) through Embase. Moreover, one additional database, 
the Centre for Reviews and Dissemination database was explored. We also searched the 
reference lists of the selected studies. A detailed search strategy including keywords is 
presented in the Supplemental materials (Supplemental Appendix 1). 
Inclusion and exclusion criteria 
After each search in the databases, the initial hits were exported into EndNote and duplicates 
were removed. The exclusion and inclusion of each study were based on the PICOS criteria 
which refer to the Population, Intervention, Comparison, Outcomes and Study design of an 
article (Supplemental Table 1). The inclusion criteria were referential to all types of 
economic evaluations (CEA, CUA, CMA, CBA) of any intervention for PD management, 
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 including drug therapies, with no limitation regarding the comparator involving PD patients 
of any severity level. The retrieved studies were assessed in two phases; firstly, titles and 
abstracts were checked, according to PICOS, and thereafter, the full text of the remaining 
articles was screened for final selection. 
Data extraction 
The data from the selected studies was extracted regarding two dimensions; the study results 
(empirical evidence) and the methods (methodology). The reporting quality of the studies 
was assessed by using the CHEERS checklist 31. The CHEERS checklist consists of 24 items 
divided into six main categories according to the articles’ structure (title and abstract, 
introduction, methods, results, discussion, and other). For computing a final score, we 
assigned one point (1) if the item was complete and zero points (0) if the requirement was not 
fulfilled. In cases where the requirements were not applicable to the subject or structure of the 
study, we assigned Not Applicable (NA). The maximum score for reporting all items 
completely was 24 points. Finally, for ease of comparison, the extracted results were 
converted to US dollars in price year 2016 32 and the local currency values are presented in 
parenthesis as exhibited in the studies. The cost is converted by using country-specific Gross 
Domestic Product (GDP) deflator indices to account for inflation. Thereafter, the price-year 
adjusted cost is converted to US dollars using Purchasing Power Parity rates 32. 
Results 
Twenty eight studies were identified in the review. The detailed selection process of the 
studies is presented in Figure 1. The main characteristics of the selected studies are 
summarized in Supplemental Table 2. The categories and sources of costs as well as the 
measures and sources of QALYs, as these were reported in the selected studies, are presented 
in Supplemental Table 3. The subsequent interventions are divided into three main categories 
for ease of presentation and discussion: 1) drug treatments; 2) deep brain stimulation (DBS); 
and 3) other therapies focusing, mostly, on physical activity and occupational therapy. The 
cost-effectiveness results in the selected studies were presented either by incremental cost-
effectiveness ratios (ICERs), i.e. the difference in costs between two alternatives divided by 
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 the difference in outcomes of the two alternatives, or by reporting costs and outcomes in the 
intervention and comparator. The interventions are generally implemented according to the 
severity level of PD. PD severity is evaluated according to the Hoehn and Yahr (H&Y) 
staging scale which combines both disability and impairment by categorizing motor and 
balance/gait dysfunctions into 5 stages 33. Stage 1 represents the initial, least severe state and 
it is assumed that patients, starting from 1, progress to stage 5 as their status deteriorates 33.  
Drug treatments  
The most common treatment for counteracting the incipient symptoms of PD is oral 
monotherapy medication, i.e. levodopa, DA or rasagiline, which is effective in reducing 
motor fluctuations. In the USA, researchers compared the cost-effectiveness of rasagiline 
versus DA (ropinirole XL, pramipexole, generic ropinirole) or versus levodopa as initial 
therapies in PD 34. Treatment with rasagiline led to more QALYs (3.45 versus 3.34, 3.34, 
3.34 for the DAs respectively, and 3.21 for levodopa), fewer patients with dyskinesia (38% 
and 73% respectively) and lower costs than ropinirole XL, pramipexole and levodopa, thus 
dominating the alternatives. Although rasagiline resulted in higher costs compared to generic 
ropinirole, it generated an ICER of $28,406/QALY ($25,939).  
Ten patients in Norway underwent a before-after prospective study and shifted their treatment 
from oral levodopa to intestinal levodopa 35. The aim was to estimate whether this transition 
was cost-effective compared to maintaining the initial oral treatment. Intestinal levodopa had 
0.047 higher QALY gain and approximately $60,533 (472,000 NOK) higher costs compared 
to oral treatment, leading to $1.18 million/QALY (NOK 9.2 million/QALY).  
Levodopa/carbidopa intestinal gel (LCIG) was compared to standard treatment for PD 
patients from a healthcare perspective in Bulgarian, UK and Irish setting36 37, 38. The 12 PD 
patients in Bulgaria exhibited improvement in UPDRS scores after the LCIG treatment with 
an ICER of $3,050/QALY (1,904 BGN). In the UK and Irish study, a Markov model was 
used, over the lifetime, where patients remained in LCIG for the first five years and then 
returned back to standard treatment 38. The ICER was estimated at $55,366/QALY (£36,024) 
in the UK and $34,823/QALY (€26,944/QALY) in the Irish Study 36. However, the results of 
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 these studies were relatively sensitive to patients’ health state during the treatment initiation 
and to the duration of the health benefits. In a Swedish study, Duodopa’s ICER compared to 
usual care amounted to $776,408/QALY (SEK 6.1 million) 39. However, inclusion of non-
medical costs, such as formal home help and informal care in the societal perspective, 
reduced the estimated ICER to $54,730/QALY (SEK 430,000). A Markov model was used to 
compare continuous subcutaneous apomorphine to adjunct therapies (standard care), and to 
levodopa/carbidopa intestinal gel (LCIG) in the UK and Germany 40. LCIG dominated 
adjunct therapies over the lifetime in both countries. However, the ICER of LCIG compared 
to continuous subcutaneous apomorphine was $355,169/QALY (£244,684) in the UK and 
$350,000/QALY (€272,914) in Germany. Moreover, apomorphine’s ICER over adjunct 
therapies in the UK was $9347/QALY (£6440). Although apomorphine could limit some 
motor functions for the patients, the researchers suggested that, from a healthcare provider’s 
perspective, it could be used as an alternative to adjunct therapies for patients not eligible to 
alternative treatments 40. 
A CEA comparing prolonged release ropinirole (PR) versus immediate-release ropinirole 
(IR) was conducted for PD patients in the Netherlands 41. Both drugs were used 
complementary to levodopa treatment. In the Markov model, the health states were based on 
the H&Y stages and the transition among these states could be performed in six-month 
cycles. The analyses, both short-term (5 years) and over lifetime, were performed from a 
healthcare providers’ perspective and only direct costs were included, i.e. drug costs, costs 
for elderly care and hospital care. PR was dominant over IR, with a QALY gain of 0.08 in the 
short-term and 0.24 in the long-term and reduced the costs of $25,444 (€19,700)) and 
$52,050 (€40,300) over 7- and 10-years period, respectively. However, indirect costs and 
outcomes were not considered, thus, an intimate apprehension was not possible.  
In one CUA, three different treatment combinations were compared to standard care 
(levodopa monotherapy) in the USA 42. The treatments were rasagiline+levodopa (RAS+LD), 
entacapone+ levodopa (ENT+LD), and levodopa/ carbidopa/entacapone (LCE). A 2-year 
Markov model was used where patients moved to different health states in every four months. 
The transition probabilities, cost, and health utilities were derived from various clinical trials 
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 and the cost-effectiveness was investigated from both the societal and payer perspective. In 
both perspectives, RAS+LD and LCE had greater effectiveness, compared to levodopa. From 
a societal perspective, ENT+LD led to $13,340/QALY ($12,031), compared to levodopa. The 
indirect costs, caregiver’s costs as well as patients’ heterogeneity were not included.  
Furthermore, no sensitivity analysis was conducted. Francois et al. 43 used a Markov model to 
explore the cost-effectiveness of droxidopa (6 months) followed by standard care (6 months) 
versus 12 months of standard care, from a payer perspective in the USA. The ICER was 
$47,528/QALY ($47,001/QALY).  
 
Deep Brain Stimulation 
A Markov model was used to determine cost-effectiveness of  DBS plus best medical 
treatment compared to best/standard medical treatment alone in two studies in the UK 44 45, in 
Germany 46 and in the USA47. The time frame for the studies was 5 years, 15 years45, 
lifetime46 and 10 years47. All the studies defined patients’ health state according to the H&Y 
stages, and the cycle lengths were one year 44 45 and 6 months 46, 47. Costs of surgery, battery 
replacement, and the cost of the adverse events were the main contributors to the total costs. 
The ICERs for the treatment options were  $31,780/QALY (£20,678) 44 , $28,867/QALY 
(£19,887/QALY)45, $9,333/QALY (€6,700/QALY) 46 and $23,870/QALY ($23,404/QALY) 
47. The results were sensitive to patients’ H&Y stage. This was further elaborated in a study 
from Japan where CUA was performed considering different PD stages of the patients (early, 
intermediate, late) 48. Using a Markov model, they showed that the ICER varied from 
$29442/QALY ($70,200/QALY) in the early, increased to $26110/QALY ($25,600/QALY) 
in the intermediate and dropped to $27,742/QALY ($27,200/QALY) in the late over the 10 
years from a healthcare perspective. 
A similar study was conducted in Hong Kong, where DBS was compared with standard 
medical treatment by following 13 patients having DBS surgery over two years 49. The 
standard care cost was estimated before the surgery. For the two-year period, the ICER was 
$134,821/QALY ($123,110) in the first year and $68,824/QALY ($62,846) in the second 
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 year. The cost was higher in the first year due to DBS surgery but reduced substantially in the 
next year. The authors suggested that the procedure might have been even more cost-effective 
during the following years, however, the sample size was relatively small 49. DBS was 
reported cost-effective compared to standard care 40 but dominated by continuous 
subcutaneous apomorphine in both the UK and Germany 40 as described in the Drug 
treatment section. 
In two studies, the cost-effectiveness of DBS procedure in two different sites; globus pallidus 
internus (GPi) and subthalamic nucleus (STN), was compared 50, 51. The first study was a 
CMA which compared the medication costs before and after the surgery, and between the 
GPi and STN approaches. The medication costs were significantly lower for both sites 
compared to best medical treatment, and STN had significantly lower costs compared to GPi 
50. In the second study, the medication costs of STN were also lower compared to GPi. The 
ICER of GPi versus STN stimulation was $109,901/QALY ($100,355) from a provider’s 
perspective and $59,280/QALY ($54,129) from a societal perspective 51. Using a previously 
used Markov model44, Dams et al 52showed that of STN DBS plus BMT had ICER 
$30,316.81/QALY (€22,710/QALY) comparing to BMT alone in Germany over the lifetime 
of 251 young PD patients. Only one study was performed alongside an RCT, the PD SURG 
trial in the UK53. The ICER was $735,200/QALY (£468,528/ QALY) at year one and was 
interpreted as not cost-effective from a health and social care perspective but the 
extrapolation of costs and outcomes in the DSA over 5 years resulted in a lower ICER 
$91,272/QALY (£45,180/QALY). 
Other therapies 
Cost-effectiveness of a physical exercise program was explored compared to usual care in 
Australia from a health system’s perspective 54. Both CEA and CUA were conducted where 
the outcomes for CEA were fall prevention and prevention of mobility deterioration, and for 
the CUA the outcome was QALYs. Fall rates had decreased among patients 6 months post-
intervention. The ICERs were $408/fall prevented (AUD 574), $6,810/person avoiding 
mobility deterioration (AUD 9,570) and $241,097/QALY (AUD 338,800). In a UK study, no 
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 differences in effect (fall prevention) or costs were observed for an exercise trial. The 
duration was 20 weeks and the comparator was usual care 55. 
Fall prevention was also evaluated in an American study of Ti Ji Quan for PD patients 56. The 
secondary outcome was QALY. Ti Ji Quan is a balance-based exercise, this was compared to 
both resistance training and stretching. The Ti Ji Quan participants had a lower number of 
falls and significantly higher QALY than both resistance training and stretching groups 
during the 9-month period. The calculated ICER of Ti Ji Quan was $3,641/QALY ($3,394). 
However, the long-term cost-effectiveness of the intervention was not observed, and informal 
caregivers’ costs were not included 56. In a Dutch setting, an evidence-based physiotherapy 
community program was assessed, compared to usual physiotherapy, as a cοmplementary 
treatment to drug therapy 57. Main outcomes were patients’ improvement in mobility and 
mobility-related quality of life. Although no differences were observed between the two 
groups in terms of health outcomes, the total costs were $939 (€727) lower in the intervention 
group. The largest cost saving in the intervention group was due to reduced informal care 
costs $404 (€313). 
The cost-effectiveness of a home-based occupational therapy program for PD patients and 
their caretakers in the Netherlands was compared with a control group receiving usual care. 
The CUA was conducted alongside a randomized controlled trial 58. There were insignificant 
differences in costs between the two groups irrespectively of inclusion or exclusion of 
informal care. The only significant difference was the lower institutional costs for the 
intervention group ($1,516/€1,458). The intervention group of patients and caregivers gained 
0.02 and 0.04 QALYs respectively over the 6-month trial period. Occupational therapy 
combined with physiotherapy was also compared with no therapy in the UK59. The CUA was 
performed alongside RCT in patients with moderate PD (H&Y 3). The ICER was 
$5,282.64/QALY (£3,493/QALY). 
In a Dutch study, 301 PD patients either participated in a multidisciplinary intervention or 
served as control following their usual care 60. The intervention included an assessment from 
a multidisciplinary team and guidance on both pharmacological and non-pharmacological 
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 therapies. The results showed that activities of daily living and quality of life (QoL) were 
slightly higher in the intervention group over the 8-month follow up (1.3 and 3.0 points 
respectively) while no differences were noted for motor outcomes or overall caregivers’ 
burden. No statistically significant differences in costs were observed. 
A CEA alongside RCT examined the cost-effectiveness of home-based motor monitoring 
plus standard in-office visits (HBMM) comparing to in-office visits alone for advanced PD 
patients in Spain61. The outcomes were UPDRS (I, II, III, IV) and QALYs and were 
examined from a healthcare perspective, throughout 1 year. The HBMM was cost-effective 
considering UPDRS outcome i.e. $191.20/UPDRS unit (€126.72/UPDRS unit) but not cost-
effective considering QALY. 
 
Discussion 
This systematic literature review evaluated all available evidence on the cost-effectiveness of 
treatment/interventions for PD patients to enrich the existing literature. Although the cost-
effectiveness of all types of PD interventions was evaluated, our findings regarding the key 
role of time horizon in defining the cost-effectiveness as well as the importance of early 
treatment initiation coincide with previous reviews 10, 28. 
Although the interventions included in this review were very heterogeneous, the 
comparability of cost-effectiveness results across the three categories of PD interventions was 
determined by various key factors, i.e. the types of analyses and comparators of treatments, 
the efficacy of interventions, the perspectives, the existing reimbursement mechanisms, and 
the diverse instruments for assessing effectiveness. Taking into account the existing 
diversification in acceptable willingness-to-pay threshold ranges; NICE’s threshold varies 
from £20,000 to £30,000/QALY gained 51, 52, the American literature mentions 
$50,000/QALY 62 and in Australian studies AUD50,000/DALY is used 54, the cost-
effectiveness results may differ in terms of generalizability and applicability across settings. 
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 In this review, NICE’s threshold is considered for determining the cost-effectiveness of PD 
interventions ($33,022- $49,533).  
For ease of discussion, we categorize PD management in two main tiers as identified by 
NICE; management of early PD (initial functional effects of the disease) and management of 
late PD (motor implications) 63. Standard care or best medical treatment, including mostly 
oral levodopa, was used as the main comparator across interventions, which eased the 
comparability of the outcomes. However, there were studies that compared the results within 
the same category of interventions 34, 35, 37, 38, 40-42, 50, 51, 56. 
Management of early PD 
Initial drug treatments and physical and occupational therapy were used in this stage. The 
contribution of physical activity and occupational therapy, in addition to usual treatment, is 
limited as most differences between the intervention and the control group in costs and 
outcomes were statistically insignificant 55, 58, 59. When QALYs were measured by the EQ-5D 
scale for physical exercise there were no significant differences in the outcomes 55, 59, and 
although a positive effect noted when measured by the SF-6D scale, the intervention was not 
cost-effective (ICER $241,097/QALY) 54. It is known that SF-6D is more sensitive in 
detecting differences in patients’ health-status, disability and medication use than EQ-5D 64.  
Ti Ji provided better results compared to other types of physical activity despite a variation in 
its cost-effectiveness. The variation derives from the use of different types of analysis; CEA 
which used natural units (falls prevented) to measure the outcome and CUA which used the 
utility measure of QALYs for the outcome. It is widely argued that CEA is more relevant to 
clinicians since the preferred type of outcome measure is therapeutic units 65. CUA is 
preferred to facilitate decision-making and increase the comparability of results 66. 
Nevertheless, the QALY underestimates the gains of short-term palliative care interventions 
and is not well suited to capture symptom improvements in elderly PD populations with a 
short lifespan 67. Hence, QALY-based results should be treated with caution since they could 
facilitate poor decision making that would, only, serve the needs of younger populations 
being in the early stages of the disease. Aiming at more robust findings, the long-term cost-
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 effectiveness of Ti Ji needs to be further explored in correlation to the duration, intensity, and 
frequency of the activities 68, 69. 
Multidisciplinary interventions, of combined drug treatments and non-medical therapy, when 
practiced in early stages led to minor improvements in QoL with the same costs 60. Indeed, 
multidisciplinary therapies help patients remain functional in their everyday life for a longer 
period, thus, not needing institutionalization or informal care 70. Institutional costs, transport 
and caregivers’ time are important categories of expenses for this type of interventions 70. 
Management of late PD 
PD management in the advanced stages prioritizes adjunct or continuous infusion drug 
therapies and surgery for soothing patients’ motor impairments. Continuous subcutaneous 
apomorphine was more cost-effective from the healthcare perspective and adjunct treatments 
appeared more cost-effective in the societal perspective. In the UK, non-oral treatments in 
advanced PD patients led to reduced healthcare costs, compared to oral therapy, expressed as 
28% less non-elective admissions to the hospital 71. We find that apomorphine is dominant 
among non-oral treatments from a healthcare perspective 40. However, when apomorphine 
was compared to levodopa/carbidopa intestinal gel the results varied according to the setting 
as the ICER was lower in the UK ($9,350) than in Germany ($108,423) 40. A possible 
explanation is that PD drug costs per patient in Germany amount to approximately €1,520 
whereas in the UK drug costs are considered the smallest component of the total costs of the 
disease 72, 73. Adjunct treatments can relieve motor symptoms and reduce adverse side effects 
leading to cost savings and long-term improvements in patients’ QoL 7. Prolonged time 
without motor symptoms lengthens patients’ mobility and lightens the burden on informal 
caregivers 74. While patients could also enjoy the benefits of this moderate symptom 
progression earlier by initiating adjunct treatments in the initial stages, prescription rates of 
single-drug therapies continue to be higher than those of adjunct drug treatment in early PD. 
The official guidelines of NICE and the Canadian Guidelines on Parkinson’s Disease, still, 
suggest monotherapy as the initial pharmacological therapy in PD patients 75, 76. Accordingly, 
prescription patterns in the USA show that almost 80% of newly treated PD patients receive 
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 single drug treatment 77. Adjunct treatments were cost-effective from a societal perspective, 
however, informal caregivers’ costs and QoL were wrongly excluded from one analysis 42, 
which, if avoided, might have indicated greater societal benefits.  
DBS was dominated by apomorphine but was more cost-effective than adjunct and standard 
drug treatments from a healthcare perspective leading to decreased medication use and a 
prolonged state of mild motor symptoms 40, 44-46, 52. According to McIntosh, a latent cost-
saving effect of DBS derives from the subsequent reduction of medication use among 
patients78. Time was an integral factor in the cost-effectiveness of DBS. Firstly, taking into 
account the progressive nature of PD, there is a clear association between undertaking DBS 
in early age (60 years) and greater cost-effectiveness ($4,740/QALY) 46, 48. Secondly, the 
costs were particularly bound to the time horizon followed, with greater reductions observed 
after the first year of surgery 49, 53. The findings from CUA alongside RCT stated that DBS 
was not considered cost-effective at first year $735,200/QALY (£468,528/ QALY) which is 
also confirmed by extrapolation analysis but its ICER was expected to fall under accepted 
thresholds in a five-year timespan53. This variation could be attributed to expensive medical 
equipment, maintenance costs and hospitalization due to surgery 28, 78. However, it is worth to 
mention that the QALY information measured by EQ-5D for DBS patients are limited in 
many studies. Only one study (the PD SURG trial) had patient level data but was limited for 
first year only53. One-year QALY data was extrapolated for 10 years in this study. 
The ICER of GPi versus STN is higher than the acceptable WTP range but STN DBS was 
cost-effective comparing to BMT52. In terms of the health outcome there is no conclusive 
evidence for the optimal site, thus researchers suggested a patient-tailored evaluation by a 
multidisciplinary professional team for choosing the DBS site 79. Nevertheless, STN had 
comparatively lower costs than GPi 50.  
Disease severity and funding source 
The observed trends of costs and outcomes showed that the costs ascended and QoL 
descended sequentially at the severe state of PD (H&Y 4.0-5.0)38, 41, 44, 48 which is in line with 
previous studies 6, 25, 80, 81. Therefore, greater cost-effectiveness can be achieved in 
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 interventions that are initiated at an early stage than later. Furthermore, the majority of 
studies referring to drug treatments and surgery was funded by pharmaceutical companies 
and only those including physical activity/occupational therapy and multidisciplinary 
interventions were funded by the government or non-governmental organizations 
(Supplemental Table 2). Generally, caution is advised in the interpretation of studies funded 
by industry, as these studies have been shown to be more prone to report favorable cost-
effectiveness ratios 82 and in the case of model-based studies, the findings tend to be even 
more problematic83.  
Reporting quality assessment 
The quality of reporting was insufficient for several articles, despite the fact that guidelines 
for conducting economic evaluations are available. Several items were partially reported or 
missing in some articles, including a proper description of costing methods such as unit costs, 
sources of costs items (registers or data from other countries), timing of the cost collection 
(prospectively or retrospectively), and methods to transform the costs from one country to 
another country. Taking into account that the CHEERS guidelines were published in 2013, 
studies published earlier than 2013 had a lower mean score (19.33) than those published in 
2013 and later (20.33). It is possible that the CHEERS statement has improved the reporting 
quality and we suggest that it should be habitually employed for further improvements in 
reporting. 
Limitations 
This study is not free of limitations. In this review, we investigated all types of intervention 
that were provided to PD patients. On one hand, the reader is presented with a comprehensive 
overview of drug interventions, DBS and other types of intervention which could be seen as a 
strength of this review. On the other hand, methodological differences between the 
interventions may have prevented in a precise way which types of interventions are most 
cost-effective. Thus, our broad approach could also be seen as a weakness. Moreover, as the 
reporting quality of the articles according to CHEERS was based on personal interpretations, 
disagreement may arise about each study’s score. In fact, a quality assessment of modeling 
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 studies using different checklists would have been interesting84. Furthermore, we have not 
assessed the methodological quality of the articles, especially for the simulation models and 
we did not perform a systematic quantitative assessment to identify key drivers of the cost-
effectiveness.  
Conclusion 
Tailoring PD management according to the subsequent cost-effectiveness of PD interventions 
should consider the absence of the cure and the progressive nature of the disease. Under 
certain restrictions, Ti Ji and multidisciplinary interventions seem to be more cost-effective 
for early PD management. In advanced PD, apomorphine was considered cost-effective from 
a healthcare perspective and adjunct treatments from a societal perspective. DBS presented 
cost-effectiveness in the long-term. However, PD progression differs depending on patients’ 
individual characteristics, levels and quality of informal care as well as disease severity. 
Hence, further research on the cost-effectiveness of individually-tailored combinations of 
existing PD interventions, with respect to patients’ own circumstances, is needed in order to 
be able to draw more robust conclusions about optimal PD management.  
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Figure 1: PRISMA flow chart for the selection of studies 
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